Compare Citius Pharmaceuticals Inc (CTXR) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Microchip Technology Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Microchip Technology Inc. trades at $75.99 (market cap $41.01B). The key difference: Microchip Technology Inc. is far larger — about 3011× Citius Pharmaceuticals Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Microchip Technology Inc. for 63 Days on average.
| CTXR | MCHP | |
|---|---|---|
Market Cap | $13.62M | $41.01B |
Volume | 132,438 | 9,972,516 |
Sector | Health | Technology |
52-Week High | $1.82 | $102.97 |
52-Week Low | $0.48 | $49.02 |
Typical Hold Time | 17 Days | 63 Days |
Enterprise Value | $3.79M | $46.13B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Microchip Technology (MCHP) trades at $75.55, down 3.17% over the past day, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, though revenue declined to $4.40B. Analyst consensus is strongly bullish with a $110.50 price target, and recent news highlights expansion in Ethernet and 48V power portfolios alongside the acquisition of Hailo to bolster edge AI capabilities.
MCHP faces near-term headwinds from profitability pressures and high debt, but long-term growth is supported by AI infrastructure demand and strategic expansions. Investment opportunities exist if operational improvements and market trends materialize, though risks include competitive intensity and execution challenges in a cyclical semiconductor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
